{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:54:45Z","timestamp":1791323685900,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,30]],"date-time":"2027-09-30T00:00:00Z","timestamp":1822262400000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K14658"],"award-info":[{"award-number":["23K14658"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cllc.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:54:03Z","timestamp":1788706443000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4354-2620","authenticated-orcid":false,"given":"Megumi","family":"Mizutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6584-1673","authenticated-orcid":false,"given":"Yoshiya","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nagamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Shiohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.09.003_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2026.09.003_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.cllc.2026.09.003_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.09.003_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.09.003_bib0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.09.003_bib0006","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with Osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.09.003_bib0007","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.09.003_bib0008","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with Amivantamab-Lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.09.003_bib0009","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1200\/JCO-24-02007","article-title":"Pragmatic randomized study of Afatinib versus chemotherapy for patients with non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: ACHILLES\/TORG1834","volume":"43","author":"Miura","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104295","article-title":"The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: the challenge is open for new therapeutic strategies","volume":"196","author":"Ferro","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0011","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0012","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus Docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0013","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.09.003_bib0014","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.09.003_bib0015","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jtho.2016.02.015","article-title":"Predictive markers for the efficacy of Anti-PD-1\/PD-L1 antibodies in lung cancer","volume":"11","author":"Shukuya","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0016","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.jtho.2021.07.027","article-title":"Differential immune-related microenvironment determines programmed cell death protein-1\/programmed death-Ligand 1 blockade efficacy in patients with advanced NSCLC","volume":"16","author":"Shirasawa","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0017","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0018","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.09.003_bib0019","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0020","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.09.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3776854","article-title":"Differences in immunological landscape between EGFR-mutated and wild-type lung adenocarcinoma","volume":"2021","author":"Luo","year":"2021","journal-title":"Dis Markers"},{"key":"10.1016\/j.cllc.2026.09.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0023","doi-asserted-by":"crossref","first-page":"9753","DOI":"10.1038\/s41598-022-13102-7","article-title":"PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment na\u00efve advanced EGFR-mutant non-small cell lung cancer patients","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2026.09.003_bib0024","doi-asserted-by":"crossref","first-page":"699","DOI":"10.21037\/tlcr-20-893","article-title":"Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma","volume":"10","author":"Kang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2026.09.003_bib0025","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1111\/cas.14156","article-title":"Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer","volume":"110","author":"Matsumoto","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2026.09.003_bib0026","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jtho.2018.07.016","article-title":"Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation","volume":"13","author":"Su","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0027","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2026.09.003_bib0028","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2026.09.003_bib0029","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.cllc.2026.09.003_bib0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2018.09.010","article-title":"Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer","volume":"125","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.09.003_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.745859","article-title":"The effect of smoking on the immune microenvironment and immunogenicity and its relationship with the prognosis of immune checkpoint inhibitors in non-small cell lung cancer","volume":"9","author":"Sun","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.634059","article-title":"Tumor immune microenvironment characteristics and their prognostic value in non-small-cell lung cancer","volume":"11","author":"Su","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.811601","article-title":"Various subtypes of EGFR mutations in patients with NSCLC define genetic, immunologic diversity and possess different prognostic biomarkers","volume":"13","author":"Lei","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2021.01.010","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer","volume":"153","author":"Zhou","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.09.003_bib0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2020.02.010","article-title":"PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy","volume":"142","author":"Chen","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.09.003_bib0036","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2026.09.003_bib0037","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.21873\/anticanres.15736","article-title":"Prognostic implication of PD-L1 expression on Osimertinib treatment for EGFR-mutated non-small cell lung cancer","volume":"42","author":"Shiozawa","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2026.09.003_bib0038","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of Atezolizumab plus Bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0039","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2020.01.005","article-title":"Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer","volume":"141","author":"Yoshimura","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.09.003_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030841","article-title":"Osimertinib resistance: molecular mechanisms and emerging treatment options","volume":"15","author":"Gomatou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2026.09.003_bib0041","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41419-024-06945-7","article-title":"PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cllc.2026.09.003_bib0042","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2026.09.003_bib0043","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.24.00533","article-title":"A multicenter open-label randomized phase II study of Osimertinib with and without Ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial)","volume":"43","author":"Le","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0044","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase 2 study of Osimertinib plus Bevacizumab versus Osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.09.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8613","article-title":"OSIRAM-1\/TORG1833: overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer","volume":"42","author":"Yoh","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:49:28Z","timestamp":1791323368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1525730426001208"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.09.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}